Diagnosis and treatment of pulmonary chronic GVHD: report from the consensus conference on clinical practice in chronic GVHD

Hildebrandt, G. C. and Fazekas, T. and Lawitschka, A. and Bertz, H. and Greinix, H. and Halter, J. and Pavletic, S. Z. and Holler, E. and Wolff, D. (2011) Diagnosis and treatment of pulmonary chronic GVHD: report from the consensus conference on clinical practice in chronic GVHD. BONE MARROW TRANSPLANTATION, 46 (10). pp. 1283-1295. ISSN 0268-3369

Full text not available from this repository. (Request a copy)

Abstract

This consensus statement established under the auspices of the German working group on BM and blood stem cell transplantation (DAG-KBT), the German Society of Hematology and Oncology (DGHO), the Austrian Stem Cell Transplant Working Group, the Swiss Blood Stem Cell Transplantation Group (SBST) and the German-Austrian Pediatric Working Group on SCT (Pad-Ag-KBT) summarizes current evidence for diagnosis, immunosuppressive and supportive therapy to provide practical guidelines for the care and treatment of patients with pulmonary manifestations of chronic GVHD (cGVHD). Pulmonary cGVHD can present with obstructive and/or restrictive changes. Disease severity ranges from subclinical pulmonary function test (PFT) impairment to respiratory insufficiency with bronchiolitis obliterans being the only pulmonary complication currently considered diagnostic of cGVHD. Early diagnosis may improve clinical outcome, and regular post-transplant follow-up PFTs are recommended. Diagnostic work-up includes high-resolution computed tomography, bronchoalveolar lavage and histology. Topical treatment is based on inhalative steroids plus beta-agonists. Early addition of azithromycin is suggested. Systemic first-line treatment consists of corticosteroids plus, if any, continuation of other immunosuppressive therapy. Second-line therapy and beyond includes extracorporeal photopheresis, mammalian target of rapamycin inhibitors, mycophenolate, etanercept, imatinib and TLI, but efficacy is limited. Clinical trials are urgently needed to improve understanding and treatment of this deleterious complication. Bone Marrow Transplantation (2011) 46, 1283-1295; doi: 10.1038/bmt.2011.35; published online 28 March 2011

Item Type: Article
Uncontrolled Keywords: VERSUS-HOST-DISEASE; STEM-CELL TRANSPLANTATION; BONE-MARROW-TRANSPLANTATION; BRONCHIOLITIS OBLITERANS SYNDROME; TOTAL LYMPHOID IRRADIATION; HIGH-RESOLUTION CT; WORKING GROUP-REPORT; LONG-TERM SURVIVORS; IDIOPATHIC PNEUMONIA SYNDROME; OBSTRUCTIVE AIRWAY DISEASE; chronic GVHD; allo-SCT; lung; obliterative bronchiolitis; treatment
Subjects: 600 Technology > 610 Medical sciences Medicine
Divisions: Medicine > Lehrstuhl für Innere Medizin III (Hämatologie und Internistische Onkologie)
Depositing User: Petra Gürster
Date Deposited: 06 May 2020 06:59
Last Modified: 06 May 2020 06:59
URI: https://pred.uni-regensburg.de/id/eprint/20035

Actions (login required)

View Item View Item